Respiratory Training in the Treatment of Transdiagnostic Pathological Anxiety
Respiratory Training in the Treatment of Transdiagnostic Pathological Anxiety: A Randomized Clinical Trial
University of Texas at Austin
180 participants
Aug 22, 2022
INTERVENTIONAL
Conditions
Summary
Purpose of the Research: The primary aim of the proposed study is to conduct a randomized parallel-group 2-arm clinical trial investigating capnometry-guided respiratory intervention (CGRI) for pathological anxiety. CGRI aims to raise end-tidal CO2 levels thereby lowering hyperventilation-induced respiratory alkalosis and its associated fear-eliciting somatic reactions. Psycho-education about anxiety and its effects (PsyEd) will serve as a credible control comparator.
Eligibility
Inclusion Criteria15
- Clinically elevated anxiety as indicated by an eight or higher on the Overall Anxiety Severity and Impairment Scale (OASIS).
- Meets DSM-5 criteria for one or more of the following anxiety or trauma-related disorders as their "primary" mental disorder:
- Generalized Anxiety Disorder
- Panic Disorder
- Health Anxiety
- Agoraphobia
- Social Anxiety Disorder
- Posttraumatic Stress Disorder
- Acute Stress Disorder
- Adjustment Disorder with primary anxious mood
- Anxiety disorder not otherwise specified
- No current use of psychotropic medications or stable on current medications for at least 6 weeks
- Age 18+.
- Able to arrange transportation to our laboratory for study appointments.
- Fluent in English.
Exclusion Criteria13
- No history of medical conditions that would contraindicate participation in fear-provocation or respiratory challenges, including:
- Cardiovascular or respiratory disorders
- High blood pressure
- Epilepsy
- Strokes
- Seizures
- History of fainting
- Pregnant or lactating
- Not currently receiving other psychological treatment for anxiety.
- No history of a suicide attempt within the past 6 months.
- No history of psychosis within the past 6 months.
- No history of moderate to severe alcohol or substance use disorder (with the exception of nicotine) within the past 3 months.
- Does not endorse COVID-19 symptoms during the screening phase.
Interventions
See: Arm/group descriptions
See: Arm/group descriptions
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05427708